<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045916</url>
  </required_header>
  <id_info>
    <org_study_id>#3891</org_study_id>
    <secondary_id>R01MH061609</secondary_id>
    <secondary_id>DSIR 83-ATSO</secondary_id>
    <nct_id>NCT00045916</nct_id>
  </id_info>
  <brief_title>Optimizing Electroconvulsive Therapy for Depression</brief_title>
  <official_title>Optimization of Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered&#xD;
      with medication for the treatment of a major depressive episode (unipolar or bipolar) and&#xD;
      will compare two types of ECT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study addresses 2 issues in the optimization of ECT in patients with major depression:&#xD;
      whether patients treated with ECT should receive concurrent treatment with antidepressant&#xD;
      medications, and the relative efficacy and side effects of high dosage right unilateral (RUL)&#xD;
      ECT compared to low dosage bilateral (BL) ECT.&#xD;
&#xD;
      This study has 2 phases. In Phase I, patients are randomized to receive nortriptyline,&#xD;
      venlafaxine (Effexor), or placebo while they simultaneously receive either high dosage RUL&#xD;
      ECT or low dosage BL ECT. Patients have an electrocardiogram (EKG), a chest x-ray, medical&#xD;
      and neurological examinations, and blood tests. Memory function is assessed before and after&#xD;
      ECT. Whenever feasible, patients are withdrawn from all prior psychotropic medication before&#xD;
      the start of ECT. ECT is administered 3 times per week to inpatients and twice a week to&#xD;
      outpatients. Patients continue ECT until they are asymptomatic or until there is a plateau in&#xD;
      improvement over 2 treatments.&#xD;
&#xD;
      Patients who respond to ECT enter Phase II and add lithium to either nortriptyline or&#xD;
      venlafaxine within 1-3 days of the last ECT. Clinical and side effect evaluations and blood&#xD;
      level determinations are conducted weekly for the first month, every 2 weeks until Week 12,&#xD;
      and every 4 weeks for the remaining 12 weeks. Following any indication of relapse, patients&#xD;
      are monitored more intensively and are re-evaluated within 1 week. The neurocognitive battery&#xD;
      is readministered to all patients at 2 and 6 months after the acute ECT course, regardless of&#xD;
      ECT clinical outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive battery</measure>
    <time_frame>Measured at baseline and at 2 and 6 months after the acute ECT course</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evaluations, side effect evaluations, and blood level determinations</measure>
    <time_frame>Measured weekly for the first month, every 2 weeks until Week 12, and every 4 weeks for the remaining 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory function</measure>
    <time_frame>Measured before and after ECT</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage ECT + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage ECT + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High dosage electroconvulsive therapy</intervention_name>
    <description>Participants will receive high dosage right unilateral ECT at six times the seizure threshold.</description>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>High dosage ECT + placebo</arm_group_label>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nortriptyline</intervention_name>
    <description>Participants will receive nortriptyline.</description>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Participants will receive venlafaxine.</description>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Participants will receive lithium.</description>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>High dosage ECT + placebo</arm_group_label>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>Low dosage ECT + placebo</arm_group_label>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Low dosage electroconvulsive therapy</intervention_name>
    <description>Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.</description>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>Low dosage ECT + placebo</arm_group_label>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major depressive episode (unipolar or bipolar)&#xD;
&#xD;
          -  Pre-ECT score of 20 or higher on Hamilton Rating Scale for Depression&#xD;
&#xD;
          -  Able to withdraw psychotropic drugs (up to 3 mg/day lorazepam allowed)&#xD;
&#xD;
          -  ECT indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Schizophrenia, schizoaffective disorder, or other psychosis&#xD;
&#xD;
          -  Amnestic disorder, dementia, or delirium&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Current alcohol or substance abuse or dependence&#xD;
&#xD;
          -  CNS disease or brain injury not associated with psychotropic drug exposure&#xD;
&#xD;
          -  ECT in the past 6 months&#xD;
&#xD;
          -  Medical contraindication for treatment with either nortriptyline or venlafaxine,&#xD;
             including allergy to amitriptyline, nortriptyline, or venlafaxine; narrow angle&#xD;
             glaucoma; sinus node disease; bundle branch disease; myocardial infarction; coronary&#xD;
             artery bypass or angioplasty; or angina&#xD;
&#xD;
          -  Type I antiarrhythmic medication&#xD;
&#xD;
          -  Supine blood pressure &gt;= 170 mmHg systolic or &gt;= 105 mmHg diastolic at 3 readings over&#xD;
             2 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold A. Sackeim, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>New York State Psychiatric Institute and Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299-307.</citation>
    <PMID>11255384</PMID>
  </reference>
  <reference>
    <citation>Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000 May;57(5):425-34.</citation>
    <PMID>10807482</PMID>
  </reference>
  <reference>
    <citation>McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000 May;57(5):438-44.</citation>
    <PMID>10807483</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 13, 2002</study_first_submitted>
  <study_first_submitted_qc>September 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2002</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electroconvulsive therapy</keyword>
  <keyword>Antidepressive Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

